INTRODUCTION
Iron is a metal critically important for cell proliferation and survival. It is an essential constituent of hemoglobin and myoglobin, mitochondrial electron transport proteins, hydroxylating enzymes, lipoxygenases and cyclooxygenases, as well as ribonucleotide reductase, the enzyme that catalyzes the rate-limiting step in DNA synthesis. Tumor cells frequently exhibit increased uptake and utilization of iron, as evidenced by an increase in transferrin receptors at the cell surface 1, 2 . This has led to the suggestion that agents that deplete intracellular iron may be useful in cancer therapy [3] [4] [5] .
A variety of approaches, including the use of antisense technology 6, 7 and antibodies 8 to target the transferrin receptor, have borne out this prediction. Indeed, gallium, a metal used in combination chemotherapy for the treatment of metastatic urothelial carcinoma 9 and nonHodgkin's lymphoma 10 , exerts its effects in part by interfering with iron metabolism.
High affinity, low molecular weight metal chelators offer a direct method of achieving intracellular iron deprivation, and the anti-tumor potential of iron chelators has also been the subject of active investigation. The preponderance of these studies have focused on desferrioxamine (deferoxamine, Desferal, DFO), a hexadentate iron chelator and the drug of choice for the treatment of chronic iron overload. Although desferrioxamine has been shown to retard tumor growth substantially in animal studies 11 and some clinical trials 12 , results have been mixed 13, 14 , and have led to the identification of chelators with potentially improved antitumor activity. For example Triapine, a ribonucleotide reductase inhibitor and iron chelator, is only.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From currently in Phase I clinical trials 15 . Pyridoxal isonicotinoyl hydrazone 16 , O-Trensox 17 , desferrithiocin 18, 19 , desferri-exochelin 20 , di-2-pyridyl thiosemicarbazones 21 and tachpyridine [22] [23] [24] [25] [26] [27] are chelators under investigation as anti-tumor agents.
Tachpyridine is a hexadentate metal chelator 23 . It is a member of a chelator family currently in pre-clinical development at the National Cancer Institute (NCI). Tachpyridine weakly binds divalent cations such as calcium, magnesium and manganese, but strongly binds iron, copper and zinc. The cytotoxic activity of tachpyridine is likely due to its ability to bind one or more of the metals iron, zinc, or copper, since complexes of tachpyridine with these metals (but not others)
are non-toxic 23 . Tachpyridine exhibits a lower IC 50 than DFO, and is preferentially cytotoxic to tumor cells 23 . Tachpyridine also retards the growth of implanted tumors in mice (Torti, et al., in preparation) .
Mechanisms underlying the anti-cancer activity of iron chelators are incompletely understood.
Ribonucelotide reductase, which contains iron at its catalytic center, is frequently cited as a target of iron chelators, although inhibition of this enzyme by iron chelators can be modest [28] [29] [30] .
Inhibition of proteins required for cell cycle progression, such as cyclins A, B, and D, and the cyclin-dependent kinases cdk1 and cdk2 31 , has also been reported. Chelators have also been reported to exert cytotoxic effects via redox cycling of bound metals and attendant production of free radicals 30, 32 . Mechanistic studies of tachpyridine have shown that it induces an apoptotic response in several cancer cell lines by activating the mitochondrial pathway 25 . In addition, the tumor suppressor protein p53 accumulates in cells treated with tachpyridine, although p53 is not required for tachpyridine-mediated apoptosis 24 .
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To gain further insight into the mechanism of action of iron chelators, and to more completely define the spectrum of tachpyridine's anti-cancer activity, we assessed the effect of tachpyridine on cell cycle regulation. We report here that tachpyridine arrests HeLa cervical carcinoma and HCT116 colorectal cancer cells at the G2 phase of the cell and activates both CHK1 and CHK2.
Activation of the CHK kinases in tachpyridine-treated cells is preceded by phosphorylation of p53 at serine 15, implicating ATM/ATR kinases in CHK kinase activation and cell cycle arrest.
ATR-mediated activation of CHK1 is critical to this response, since G2 arrest is blocked by either UCN-01, a CHK1 inhibitor, or genetic knockdown of ATR. Consistent with its ability to induce G2 arrest, tachpyridine selectively sensitized cancer cells to ionizing radiation.
Collectively, these results suggest that chelators may function in anti-cancer therapy as radioenhancing agents as well as cytotoxic agents. These results also indicate a previously unexplored activity of metal chelators in activation of ATM/ATR and the checkpoint kinases.
MATERIALS AND METHODS

Chemicals.
Tachpyridine and N-methyl tachpyridine were synthesized from cis-1,3,5-triaminocyclohexane according to methods published previously 22, 33 and were prepared as a 1mM stock in phosphate-buffered saline (PBS), pH 7.4, 0.22µ filter sterilized, and stored at 4°C. Boehringer Mannheim, Indianapolis, IN) and phenylmethylsulphonyl fluoride (0.1mg/ml).
Primary antibodies used in western blotting were mouse anti-human p53 monoclonal antibody (Ab-6; Calbiochem, San Diego, CA), rabbit anti-human phosphorylated serine-15 p53, rabbit anti-human phospho serine-345 CHK1, rabbit anti-human phospho threonine-68 CHK2, and monoclonal anti-ATM antibody (Cell Signaling, Beverly MA). ATR immunoblotting was conducted using a rabbit polyclonal antibody that was raised using a bacterially-synthesized, purified GST-ATR fusion protein as the immunogen (D. Beardsley and K. Brown, unpublished) . Cells were plated in 24-well dishes, exposed to tachpyridine for 12 hours, irradiated, washed, and allowed to grow for approximately 7 days. MTT was administered for 4 hours and cells were lysed at least overnight. Aliquots were transferred to 96-well plates, and absorbance at 560nm measured.
RESULTS
Tachpyridine induces G2/M cell cycle arrest. Tachpyridine is a metal chelator of potential
clinical use as an anticancer agent 23 24 . In order to probe the mechanism of action of this chelator, we assessed its effects on the cell cycle. As shown in For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From cytotoxicity, excluding the possibility that the accumulation of cells in G2/M was an artifact resulting from selective cytotoxicity of tachpyridine to cells in G0/G1 and S (data not shown).
Cell cycle arrest requires metal binding activity. Our previous work has demonstrated that cytotoxic effects of tachpyridine are critically dependent on its metal binding activity, and that N-alkylated derivatives of tachpyridine that are unable to bind metals are non-toxic 23 . To test whether tachpyridine's effects on the cell cycle were similarly dependent on its metal binding activity, we assessed the cell cycle effect of N-methyl tachpyridine, an analog inhibited in its ability to bind iron due to steric constraints and an inability to undergo oxidative dehydrogenation 22 . As shown in Table I , N-methyl tachpyridine was unable to induce G2/M cell cycle arrest. Thus, the ability of tachpyridine to induce G2/M arrest is linked to its metal binding activity. G2/M is the most radiosensitive phase of the cell-cycle 37 , and agents that arrest cells in G2/M are known to be effective radiosensitization agents (reviewed in 38, 39 ). Since tachpyridine arrests cells in G2, experiments were performed to determine if it acts as a radiosensitizer in cancer cells. We initially assessed radiosensitization in HCT 116 cells by clonogenic survival assays.
Tachpyridine arrests cells in G2 and
As anticipated, exposure of HCT 116 cells to ionizing radiation (IR) led to a dose-dependent decrease in cell survival compared to untreated cells (Fig. 3C) . We then tested whether pretreatment with tachpyridine would augment the sensitivity of these cells to IR. Cells were pretreated for 12 hours with 7.5 µM tachpyridine. This dose was selected because it only modestly decreased cell survival in response to tachpyridine alone (data not shown), and therefore facilitated assessment of the combined effects of tachpyridine and IR. After the 12 hour pretreatment, cells were exposed to IR and allowed to recover for one hour. Tachpyridine was then removed, and surviving cells were allowed to form colonies. As shown in the clonogenic survival curves depicted in Fig. 3C , tachpyridine increased the sensitivity of cells to the cytotoxic effect of ionizing radiation. The reduction in survival in cells pretreated with tachpyridine before exposure to IR was greater than that achieved with either tachpyridine or IR alone. Radioenhancement occurred at low levels of IR (1, 2, and 4 Gy), which represent clinically relevant doses of ionizing radiation exposure.
We also addressed the contribution of p53 to the radiation sensitization effect by using p53 knock-out HCT 116 cells. As with the wild-type cell line, p53 knock-out cells were also radioenhanced by tachpyridine (Fig. 3D) . Furthermore, these cells were sensitized to the same extent as p53 wild type cells, indicating a p53-independent radiosensitization response. wild-type cell line, a DER value at 10% SF of 1.39 ± 0.15 SEM (N=3) was calculated (Fig. 3C) .
The p53 knock-out HCT 116 cell line produced a DER value at 10% SF of 1.35 ± 0.04 SEM (N=3) (Fig. 3D) . Tachpyridine does not enhance the sensitivity of non-cancer cells to ionizing radiation. The effect of radiation in normal tissue is an important consideration when studying radioenhancers.
The desired effect is to achieve greater cytotoxicity in the tumor cell environment with little effect in the surrounding normal tissue, thus preventing undesirable side effects. In order to only.
For Based on these results, the MTT assay was used to assess whether tachpyridine enhances radiation sensitivity in normal cells. As shown in Fig. 3F , in contrast to the cancer cell lines we studied, tachpyridine does not enhance the effect of radiation in MRC5 cells. This observation is true even at four times the dose of tachpyridine and doses of IR as high as 10 Gy (Fig. 3F) .
Tachpyridine activates cell cycle checkpoint kinases. To explore the mechanism of tachpyridine-mediated G2 arrest, we tested the involvement of the checkpoint kinases. These kinases induce G2 arrest in response to genotoxic stress, at least in part through phosphorylation of Cdc25C 41, 42 . CHK1 is activated primarily in response to UV damage and replication arrest 34, 43, 44 , whereas CHK2 is activated in response to ionizing radiation 45, 46 . However, recent work has suggested the existence of cross-talk between these two pathways [47] [48] [49] [50] . To test whether tachpyridine activated the CHK kinases, HeLa cells were treated with 7.5 and 10µM
For To test the relative contribution of each of these kinases to tachpyridine-mediated cell cycle arrest we first examined the ability of tachpyridine to induce cell cycle arrest in CHK2 knockout cells. We found that cell cycle arrest by tachpyridine proceeded in CHK2 knockout cells: the fraction of cells in G2/M rose from 17 ± 5% to 39 ± 8% (SD, n=3) in cells treated with 7.5 or 10 µM tachpyridine, indicating that CHK2 is dispensible for tachpyridine-mediated cell cycle arrest.
We also examined the effect of UCN-01, a CHK1 kinase inhibitor, on cell cycle arrest mediated by tachpyridine. As shown in Table II We also used caffeine to confirm the importance of CHK1 in triggering G2 arrest. As shown in Fig. 5B , the inhibition of G2 arrest by caffeine was accompanied by a block in CHK1 phosphorylation, whereas CHK2 phosphorylation was not affected. These results are consistent with an important role in tachpyridine-mediated G2 arrest, and suggest that the role of CHK2 may be less critical.
To probe whether ATM or ATR was the proximal kinase responsible for tachpyridine-mediated G2 arrest, we first tested the ability of tachpyridine to induce G2 arrest in isogenic ATM deficient and reconstituted cells 35 . As shown in Figure 6A and B, tachpyridine induced an equivalent arrest regardless of the status of ATM, indicating that ATM is dispensable for tachpyridine-induced G2 arrest. To probe the role of ATR, we used HCT116 cells containing a single functional ATR allele into which lox sites flanking exon 2 of the ATR gene have been introduced by homologous recombination 34 . As previously observed, endogenous levels of ATR (Fig. 6D) . Furthermore, infection of ATR flox/-cells with a recombinant adenovirus expressing cre recombinase (Ad-cre) further reduces ATR levels. As shown in Fig. 6C , tachpyridine-mediated G2 arrest was not observed in ATR deficient cells in either the presence or absence of Ad-cre. Thus, a reduction in ATR levels abrogates tachpyridine-mediated G2
arrest, indicating the importance of ATR in activating G2 arrest in response to tachpyridine.
DISCUSSION
The potential uses of iron chelators in the treatment of human disease, including neurodegenerative diseases, ischemia-reperfusion injury, iron overload and cancer are areas of active investigation. Several iron chelating agents are currently in cancer clinical 15 and preclinical 16, 17 trials. An understanding of the intracellular mechanisms of action of iron chelators may be beneficial in optimizing their efficacy, as well as providing fundamental insights into the nature of intracellular targets of iron chelation. Here we explore the mechanism of action of tachpyridine, a member of a chelator family currently in preclinical development with the NCI as a cancer therapeutic.
In this manuscript, we show that tachpyridine arrests cells in the G2 phase of the cell cycle. This result was unanticipated, since the majority of iron chelators arrest cells at the G1/S boundary 4, [28] [29] [30] [56] [57] [58] . Although tachpyridine preferentially binds iron, it can also bind copper and zinc 27 and these activities may underlie its ability to arrest cells in G2. Alternatively or additionally, only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From tachpyridine may induce a form of genotoxic stress different from that induced by other iron chelators, and this may trigger G2 arrest. Our results demonstrate that ATR and CHK-1 are critical mediators of tachpyridine-induced G2 arrest. We also provide evidence that an important consequence of tachpyridine-mediated G2 arrest is the selective sensitization of cancer cells to ionizing radiation. A working model for the mechanism of G2 arrest induced by tachpyridine is shown in Fig. 7 .
Checkpoint kinases are activated in response to cellular stress, such as DNA damage. A major role of these kinases is the triggering of cell cycle arrest to enable DNA repair. The activation of CHK1 or CHK2 is in part dependent on the type of DNA damage. For example, ionizing radiation primarily activates CHK2, whereas replicative stress and UV activate CHK1, although overlap between these pathways exists [47] [48] [49] [50] 59, 60 . Thus, DNA damage induced by exposure to alkylating agents activates both CHK1 and CHK2 50 . Similarly, we found that tachpyridine activates both CHK1 and CHK2 (Fig 4A) . The time course of activation of both kinases was comparable, suggesting that they are activated simultaneously.
Despite the activation of both CHK1 and CHK2, our experiments suggest that CHK1 may play the principal role in triggering G2 arrest in response to tachpyridine. First, inhibition of G2 arrest in cells treated with caffeine was associated with inhibition of tachpyridine-induced CHK1 phosphorylation (Fig 5) . In contrast, under these same conditions, caffeine did not block phosphorylation of CHK2. Second, G2 arrest was not blocked in CHK2 knockout cells. Finally, UCN-01, a CHK1 kinase inhibitor, blocked tachpyridine-mediated G2 arrest (Table II) .
However, since neither caffeine nor UCN-01 are entirely selective in their inhibitory activity 34 only.
For 61 , and since CHK1 and CHK2 exhibit partial redundancy, we cannot completely exclude the possibility that under selected circumstances CHK2 can be recruited by tachpyridine and substitute for CHK1.
Known upstream activators of the CHK kinases include the ATM/ATR/ATX family of PIKK kinases. ATM and ATR participate in the response to DNA damage by recruiting multiprotein DNA repair complexes to sites of DNA damage. To test whether activation of these upstream kinases might be responsible for phosphorylation of the CHK kinases, we first examined the phosphorylation of p53 at serine 15 in cells treated with tachpyridine. P53ser15 is a known substrate of the ATM/ATR kinases [51] [52] [53] . Although some studies suggest that DNA-PK may also phosphorylate p53 at serine 15 62, 63 , this finding is controversial 62, [64] [65] [66] [67] [68] . We observed that p53 accumulated and was phosphoryated at serine 15 in a time-dependent manner, with phosphorylation observed as early as 3 hrs (Fig 4B) . This timepoint preceded activation of the CHK kinases (activated at 8-12 hrs, Fig 4A and 5B) , and is consistent with the model shown in The second line of evidence supporting the involvement of ATM/ATR in tachpyridine-mediated cell cycle arrest is our finding that caffeine, an inhibitor of the PIKK kinases, abrogated G2 arrest (Fig. 5A) . Further, ATR may be more critical than ATM in triggering the G2 response to tachpyridine. Thus, G2 arrest proceeded in cells genetically deficient in ATM (Fig. 6A,B) . In contrast, G2 arrest was not detected in HCT116 cells containing reduced levels of ATR. Since knockout of ATR is lethal, these HCT116 cells were designed to conditionally knockout ATR only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From expression following introduction of cre recombinase 34 . However, we and others 34 59 have found that these cells express reduced levels of ATR even in the absence of cre. As shown in Fig. 6C and D, HCT116 ATR deficient cells did not exhibit G2 arrest in response to tachpyridine, indicating that unlike ATM, ATR is required for G2 arrest.
Despite our observation that p53 accumulates and is phosphorylated in cells treated with tachpyridine (Fig 4B) , our data suggest that p53 does not play an essential role in tachpyridinemediated apoptosis 24 or cell cycle arrest (Fig 3) . We have previously shown that p53 activated in response to tachpyridine is not fully transcriptionally competent, since p21, a transcriptional target of p53, is not induced in cells treated with tachpyridine 24 . Although the nature of the block to p53-dependent transactivation in tachpyridine-treated cells remains unclear, this block may limit the contribution of p53 to both apoptosis and cell cycle arrest, since transcriptional targets of p53 (e.g. bax, DR5, p21) contribute to both pathways. Ultimately, the ability of tachpyridine to enhance the response to ionizing radiation in a p53-independent manner may enhance its therapeutic utility, due to the widespread loss of the p53 pathway in human cancer 69, 70 .
There are potentially important clinical ramifications for our findings. Because the G2/M phase of the cell cycle is the most sensitive to ionizing radiation 71-75 , and we had observed striking G2
arrest with sublethal doses of tachpyridine, we explored the ability of tachpyridine to sensitize cells to the cytotoxic effects of ionizing radiation. We pretreated cells with tachpyridine prior to exposing them to ionizing radiation. Tachpyridine pretreatment enhanced the sensitivity of HCT116 and RKO colon cancer cells to clinically relevant doses of ionizing radiation, and did so only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From via a p53-independent mechanism (Fig. 3) . Importantly, the sensitivity of non-cancer MRC5 cells to ionizing radiation was not similarly enhanced (Fig. 3F) . In addition, the dose enhancement ratio (DER) values derived from radiation survival curves with tachpyridine were comparable to those reported in the literature for clinically useful radiosensitizers, such as 5-fluorouracil (5-FU) 40 . Notably, the concentrations of tachpyridine required to achieve radiosensitization are readily achievable in vivo (McCormack J., Planalp, R.P., and Torti, S.V., unpublished observations). Our experiments therefore provide evidence that the iron chelator tachpyridine functions as a radioenhancer, an effect separable and distinct from our previous work that showed that tachpyridine functions as a cytotoxic agent.
Although the ability of other iron chelators to serve as radiosensitization agents has been observed (these include DFO, deferiprone, HBED, and mimosine) 76 , not all reports are consistent [77] [78] [79] , and molecular mechanisms of chelator-mediated radiosensitization are poorly understood. However, one study using mimosine demonstrated that mimozine radiosensitized the human lung cancer cell lines H460 and H358 76 , which differ in p53 status, consistent with our results that tachpyridine sensitizes cells to ionizing radiation via a p53-independent mechanism (Fig. 3 ).
An additional implication of these experiments is that they suggest a point of convergence in the mechanism of action of different iron chelators. Unlike the G2 arrest reported here for tachpyridine, cell cycle arrest induced by other iron chelators typically occurs at the G1/S boundary 4, [28] [29] [30] [56] [57] [58] . This effect is generally attributed to inhibition of ribonucleotide reductase, an iron-dependent enzyme 80, 81 that catalyzes the rate-limiting step in DNA synthesis. For only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From example, this enzyme is inhibited by desferrioxamine, a chelator in current clinical use in the treatment of iron overload, as well as by Triapine, a chelator in clinical trials as an anti-cancer agent. Since replication arrest also represents a trigger for activation of a DNA damage cell cycle checkpoint, activation of checkpoint kinases CHK1 and CHK2 may represent a point of convergence for iron chelators regardless of their proximal target. i.e., the CHK kinases may be a focal point for a variety of iron chelators that target G1/S as well as those that target G2/M. Cell stresses that underlie the activation of CHK kinases by chelators remain to be elucidated, but are likely to include metal depletion and/or genotoxic stress, which can be induced directly or indirectly by metal chelators 82 . Further experiments will be required to fully define these mechanisms.
In summary, we have shown that tachpyridine triggers activation of the CHK kinases via an ATR-dependent mechanism, leading to cell cycle arrest in G2. This is accompanied by a striking sensitization to ionizing radiation, which may have clinical implications. These studies suggest for the first time that ATR and the CHK kinases are targets of iron chelation.
from the National Institutes of Health. Preclinical development of tachpyridine was supported by a grant from the National Cancer Institute Rapid Access to Intervention Development -/-cells were pretreated with 7.5µM tachpyridine for 12 hours, followed by irradiation at 1, 2, and 4 Gy, and clonogenic survival determined as described in Materials and Methods. (E) HCT116 p53 +/+ cells were pretreated with 7.5µM tachpyridine for 12 hours, followed by irradiation at 1, 2, and 4 Gy, and viability determined by the MTT assay as described in Materials and Methods. (F) MRC5 fibroblast cells were pretreated with 25 or 30µM tachpyridine for 12 hours, followed by irradiation at 6 and 10 Gy, and viability determined by the MTT assay. Data shown is the mean and SE of 3 independent experiments performed in triplicate. tachpyridine and analyzed by western blotting using phospho-specific antibodies against activated CHK1 (S-345) and CHK2 (T-68). β-actin was included as a loading control. (B) HeLa cells were treated with 10µM tachpyridine and analyzed by western blotting using a phosphospecific antibody against phosphorylated p53 (S-15). Equivalent loading of protein was confirmed by Ponceau S staining of the transfer membrane (not shown). Tachpyridine activates ATR (and possibly ATM), which phosphorylates p53 on serine-15, followed by phosphorylation of CHK1 and CHK2. The CHK kinases then signal G2 arrest through phosphorylation of key substrates important for G2 to M progression. Signaling events not required for G2 arrest are indicated by grey dashed lines.
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